Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia

Acta Psychiatrica Scandinavica
D Jonsson, J Wålinder


The costs and effects of clozapine treatment of refractory schizophrenic patients have been discussed recently. This study shows that 18 months of clozapine treatment results in an improvement of symptoms and social functioning in approximately 70% of treatment-refractory schizophrenic patients, compared with treatment with conventional neuroleptics during a similar period of time. Treatment with clozapine reduces the cost of inpatient care but places increased demands on active rehabilitation resources in outpatient care. This leads to increased total costs in a short-term perspective, but clozapine treatment is cost-saving for annual maintenance therapy. These costs must be weighed against the positive effects on psychotic symptoms and social functioning.


Feb 19, 1999·Epidemiologia e psichiatria sociale·M Percudani, M Knapp
Jan 5, 2002·The Journal of Nervous and Mental Disease·M J SernyakG Ripper
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·D Taylor, K Aitchison
Sep 6, 2013·Acta Psychiatrica Scandinavica·S GeeD Taylor
Jun 5, 2003·The Psychiatric Clinics of North America·John G Csernansky
Apr 22, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Marco BarbieriAdrian Towse
Jul 4, 2002·Journal of Psychopharmacology·K P HayhurstS W Lewis
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·M Knapp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The British Journal of Psychiatry : the Journal of Mental Science
K J Aitchison, R W Kerwin
Psychiatric Services : a Journal of the American Psychiatric Association
J J Boronow
The International Journal of Neuropsychopharmacology
R Di LorenzoS Genedani
The British Journal of Psychiatry : the Journal of Mental Science
T G SuleimanO B Orija
© 2021 Meta ULC. All rights reserved